Top Markets
#1 NKN NKN +142.36%
#2 Bluwhale Bluwhale +36.36%
#3 Codatta Codatta +30.21%
#4 SAFEcoin SAFEcoin +28.21%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +18.53%
#7 Arcblock Arcblock +16.26%
#8 Yooldo Games Yooldo Games +15.55%
#9 Particle Network Particle Network +14.54%
#10 Ski Mask Dog Ski Mask Dog +14.15%
Coin of the day
NKN NKN
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Pozycja w akcjach #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Cena akcji
$0.15
Kapitalizacja rynkowa
$4.96M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel Intellipharmaceutics International Inc. (IPCIF)

Kategoria

Healthcare
Historia stopy dywidendy dla Intellipharmaceutics International Inc. (IPCIF)
Stopa dywidendy (TTM) dla Intellipharmaceutics International Inc. (symbol akcji: IPCIF) na dzień 2021-11-30 wynosi: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Intellipharmaceutics International Inc. (IPCIF) od 1999 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
2026 (TTM) 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% 0.00%
2000 0.00% 0.00%
1999 0.00% 0.00%
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.72%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
0.48%
US
UCB SA UCB SA
UCB SA
UCB.BR
0.48%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL